What Oncidium Foundation does

Oncidium Foundation is a Belgium-registered nonprofit (company number 0838.388.420, headquartered in Brussels) founded in 2020 with the mission of driving equal global access to radioligand therapy (RLT) for cancer care. The organisation operates across four pillars — Access, Awareness, Advocacy, and Research/Supporting Collaborations — and structures its work around a treatment-donation channel rather than a research or commercial pipeline.

Its flagship initiative is RLT-Connect, a treatment-donation platform that connects cancer patients in financial need with radiopharmaceutical therapies by drawing on a multi-manufacturer supply chain (medical radioisotopes such as Lu-177, and ready-to-use radiopharmaceuticals including 177-Lu-PSMA). Supporting products include an interactive global therapy-center map covering 950+ sites, a 70-country ambassador network of patient advocates, the Mr. Bind educational comic/video series, the Radiotheranostics Today newsletter, and a patient-information portal spanning 11 cancer types (prostate, neuroendocrine tumours, thyroid, breast, kidney, skin, hepatocarcinoma, colorectal, pancreatic, and leukemia). Distribution is web-native and content-led (WordPress CMS, social channels on LinkedIn, Instagram, X, Facebook, YouTube) plus in-country ambassador activity and partnership-driven advocacy at institutions including the European Parliament and the IAEA.

The business model is charitable: revenue comprises individual donations, institutional grants, and corporate sponsorships from radiopharmaceutical manufacturers (Curium, Isotopia, ITM, Telix, PanTera, Shine Medical Technologies, Marken) and logistics partners. Services are free to end beneficiaries. Customer segments are cancer patients (primary), healthcare professionals (oncologists, nuclear-medicine specialists), and partner organisations (radiopharmaceutical companies, patient organisations, healthcare institutions). The foundation is governed by a board operating under conflict-of-interest procedures compliant with the Belgian Code of Companies and Associations.

Name

Oncidium Foundation

Legal name

Oncidium foundation

Website

https://oncidiumfoundation.org

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Oncidium Foundation is a Belgium-based nonprofit founded in 2020 that drives equal global access to radioligand therapy for cancer care through its RLT-Connect treatment-donation platform, a 70-country ambassador network, and 950+ partner therapy centres.

Ownership category

akta.pro rank

Product category

Nonprofit Cancer Treatment Access / Radioligand Therapy Advocacy

NAICS

Voluntary Health Organizations (813212)

SIC

Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI)

akta.pro secondary industries

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC), Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

Keywords

• Radioligand therapy access
• Cancer treatment donation
• Radiotheranostics education
• Patient advocacy services
• Therapy center locator

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others, Technology or R&D

Revenue model

1. Donations and Charitable Contributions: As a foundation, Oncidium generates revenue through donations from individuals, corporations, and institutional donors to fund treatment access programs, education initiatives, and advocacy work.
2. Corporate Sponsorships: Partnerships with radiopharmaceutical companies (Curium, Isotopia, ITM, Telix, PanTera, and others) who sponsor the foundation's mission to expand access to radioligand therapy worldwide.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

Oncidium Foundation is a nonprofit foundation that drives equal access to radioligand therapy (RLT) for cancer patients worldwide. Its flagship offering is RLT-Connect, a treatment donation platform that channels donated medical radioisotopes and radiopharmaceuticals (e.g., Lu-177, 177-Lu-PSMA) to cancer patients in financial need, one patient at a time. Complementary offerings include a global therapy center locator map (950+ centers), a 70-country ambassador network, and patient education resources (Mr. Bind comic series, Radiotheranostics Today newsletter, multi-cancer-type patient guides).

Product overview

Oncidium Foundation operates as a healthcare access organization offering a portfolio of interconnected programs and platforms centered around radioligand therapy (RLT) for cancer treatment. The core offering is RLT-Connect, a treatment donation platform that connects patients in financial need with radiopharmaceutical therapies. Supporting this are an interactive global therapy center map (950+ centers), an ambassador network spanning 70 countries, educational resources including the Mr. Bind comic book series and Radiotheranostics Today newsletters, and a comprehensive patient support platform covering information on multiple cancer types. The organization functions as a foundation facilitating access, awareness, and advocacy rather than a traditional technology product company.

Differentiator

Problem solved

Functional benefit

Brands

• RLT-Connect: Treatment donation program facilitating access to radioligand therapy for patients in financial need worldwide.
• Radiotheranostics Today

Products and services

• RLT-Connect Treatment Donation Program A treatment donation platform that builds access to radioligand therapy for cancer patients in financial need, channeling donated medical radioisotopes (e.g., Lu-177) and radiopharmaceuticals (e.g., 177-Lu-PSMA) one patient at a time through partner hospitals and corporate sponsors such as Curium, Isotopia, ITM, PanTera, Shine Medical, and Marken.
• Interactive Global Therapy Center Locator Map An interactive worldwide map listing 950+ radioligand therapy centers, enabling patients and clinicians to identify the nearest qualified treatment location.
• Mr. Bind Educational Comic Book and Video Series An educational comic book and video series featuring the character Mister Bind that explains radiotheranostics concepts in plain language for patients, caregivers, and the general public.
• Patient Support Platform An online platform providing information and guidance for cancer patients across 11 cancer types (prostate, NETs, thyroid, breast, kidney, skin, hepatocarcinoma, colorectal, pancreatic, leukemia, plus others), including clinical trial information and patient stories.
• Radiotheranostics Resources Portal and Radiotheranostics Today Newsletter An online resources portal and recurring newsletter (Radiotheranostics Today) providing educational materials about radiotheranostics for healthcare professionals and patients.

Quantifiable outcome

• 74+ lives impacted through RLT-Connect treatment donation program
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

15 partnerships are on record, tiered core and flagship.

• CuriumcoreStrategic or Co-development Partner · 11 May 2026Partnership signed during Belgian Economic Mission to Turkiye to strengthen supply chain of RLT-Connect program. Curium provides medical radioisotopes (Lu-177) and ready-to-use radiopharmaceuticals (177-Lu-PSMA) as main supplier. Curium is a global radiopharmaceutical leader bringing manufacturing and distribution expertise.
• IsotopiacoreStrategic or Co-development PartnerCorporate sponsor and RLT-Connect partner providing medical radioisotope products for treatment donation program.
• ITM Isotope Technologies MunichcoreStrategic or Co-development PartnerCorporate sponsor and RLT-Connect partner, supplying medical radioisotopes for radioligand therapy access programs.
• Telix PharmaceuticalscoreStrategic or Co-development PartnerCorporate sponsor supporting foundation's mission to expand access to radioligand therapy worldwide.
• PanTeracoreStrategic or Co-development PartnerCorporate sponsor and RLT-Connect partner contributing to radiopharmaceutical supply chain.
• Shine Medical TechnologiescoreStrategic or Co-development PartnerRLT-Connect partner providing medical radioisotope production for treatment donation program.
• MarkencoreStrategic or Co-development PartnerCorporate sponsor and RLT-Connect partner specializing in logistics for radiopharmaceutical distribution.
• International Atomic Energy Agency (IAEA)flagshipStrategic or Co-development PartnerInstitutions & Programs partner collaborating on nuclear medicine and radiopharmaceutical therapy access initiatives.
• ALASBIMNcoreStrategic or Co-development PartnerInstitutions & Programs partner in Latin American nuclear medicine community supporting radiotheranostics access.
• Accelerate EU ProjectcoreStrategic or Co-development PartnerEuropean project partner working on accelerating access to radioligand therapy in Europe.
• TheracoreStrategic or Co-development PartnerInstitutions & Programs partner contributing to nuclear medicine therapy access initiatives.
• INCA (Instituto Nacional de Cancer)coreStrategic or Co-development PartnerBrazilian National Cancer Institute as Institutions & Programs partner supporting radioligand therapy access in Brazil.
• Hospital de AmorcoreStrategic or Co-development PartnerBrazilian healthcare institution as Institutions & Programs partner providing cancer treatment access.
• Fundación ACIAPOcoreStrategic or Co-development PartnerPatient organization partner in Argentina working with Oncidium on advocacy for insurance coverage expansion.
• SPARC EuropeflagshipStrategic or Co-development PartnerEuropean partner that invited Oncidium Foundation CEO to European Parliament panel on RLT policy and reality.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• American Cancer Society: The largest US cancer-focused nonprofit, providing patient support, advocacy, and access programs comparable in mission to Oncidium's cancer access and education work, though operating at much broader scale across all cancer types rather than RLT-specific.
• Clinton Health Access Initiative (CHAI): Large global health access organization negotiating pricing and supply agreements for therapies in LMICs—analogous function to Oncidium's radiopharma negotiation role but at pharmaceutical-level scale and scope.

Emerging players

• International Myeloma Foundation: Dedicated cancer-type foundation providing patient education, access support, and advocacy—comparable in mission and operating model to Oncidium but focused on a single disease rather than a single therapy modality.
• LUNGevity Foundation: Cancer-specific nonprofit combining research funding, patient education, and advocacy—parallel to Oncidium's Access/Awareness/Advocacy pillars at smaller disease-specific scale.
• Cancer Research Institute: Cancer-focused nonprofit funding immunotherapy research and patient education—comparable foundation operating model but with research orientation rather than Oncidium's treatment access focus.

Direct peers

• Direct Relief: A nonprofit focused on expanding access to medical treatments for underserved populations globally, analogous to RLT-Connect's donation model connecting patients to therapies they could not otherwise afford.
• IAEA Rays of Hope Initiative: The IAEA's flagship program to expand access to nuclear medicine and radiopharmaceutical therapies in low- and middle-income countries—directly aligned with and a partner of Oncidium, and a potential future channel-participant in the same access space.
• Project HOPE: Global health nonprofit operating in 100+ countries providing medicines, supplies, and health system support—comparable international scale and donation-supported healthcare access model to Oncidium.
• National Patient Advocate Foundation: US nonprofit providing case management and access support to patients facing serious illness, including navigating insurance and reimbursement—directly parallel to RLT-Connect's patient navigation function.
• European Cancer Patient Coalition: Umbrella pan-European patient advocacy organization that represents cancer patients in EU policy discussions including reimbursement and access—closely aligned with Oncidium's European Parliament advocacy work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/OncidiumFoundat
• YouTubeyoutube.com/@oncidiumfoundation9833
• Facebookfacebook.com/oncidiumfoundation
• LinkedInlinkedin.com/company/oncidium-foundation
• Instagraminstagram.com/oncidium_foundation

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncidium Foundation